Grigoris Gerotziafas: The Evolving Landscape of Genetic Risk Assessment in VTE
Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn about a recent article he and his colleagues co-authored, published in Polish Archives of Internal Medicine, adding:
”The VAS Group is pleased to announce the publication of our latest review article in the Polish Archives of Internal Medicine (PAIM):
‘Inherited thrombophilia and polygenic risk scores in venous thromboembolism: from classical testing to genomic risk prediction’
This is an updated overview of the evolving landscape of genetic risk assessment in venous thromboembolism (VTE), moving from conventional inherited thrombophilia testing toward next-generation genomic and polygenic risk prediction approaches.
Key messages of the review include:
- The complex interaction between genetic, acquired, and environmental determinants of VTE
- The current and future role of classical thrombophilia testing (Factor V Leiden, Prothrombin G20210A, antithrombin, protein C and protein S deficiencies)
- The emergence of genome-wide association studies (GWAS)-derived polygenic risk scores as innovative tools for individualized VTE risk stratification
- The potential integration of genomic medicine into precision thrombosis prevention and management
- The major scientific and clinical barriers that still limit implementation in routine clinical practice
This publication highlights the growing importance of precision medicine and translational vascular science in the management of thrombotic disease.
Congratulations and sincere thanks to all co-authors and collaborators for this excellent international collaborative work.”
Title: Inherited thrombophilia and polygenic risk scores in venous thromboembolism: from classical testing to genomic risk prediction
Authors: Benilde Cosmi, Grigoris Gerotziafas, Peter Marschang, Matija Kozak, Mariella Catalano, Agata Stanek

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering